Nathalie Compagnone, Nicolas Pelletier and Clotilde Biscarrat
Scientific Tracks Abstracts: J Neurol Neurophysiol
Alzheimer?s disease (AD) is diagnosed at a stage where neuronal loss is important, leading to severe cognitive deficits. Yet it is difficult to diagnose because of confounding clinical manifestations similar in other dementias. Clinicians thus resort to the longitudinal neurologic observation of disease progression, associated with biological markers such as Aβ 1-42, t-tau and p-tau CSF level and the measure of associated neuroanatomical insults using neuroimaging. Mild cognitive impairment (MCI) precedes AD, but is also present during normal or pathological ageing associated with other dementias. Over the course of 5 years, 50 to 70% of MCI patients will develop AD. ICDD is interested in the identification of prodromal markers of AD associated with disease progression. ICDD is a partner of the IMI/PharmaCog, consortium dedicated to the identification of new tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. For this purpose, specific and robust biological markers are needed to follow disease progression and its potential reversal by disease-modifying drugs. Our efforts are focused on the validation of a novel set of inflammatory blood markers within a cohort of 150 patients followed longitudinally for 3 years. An overview of the validation stage of existing blood biomarkers is presented, with a particular focus on inflammation markers. We will also present the two discovery platforms used to generate the marker sets being validated in the PharmaCog consortium using proprietary cellulomic and proteomic technologies.
Alzheimer?s disease (AD) is diagnosed at a stage where neuronal loss is important, leading to severe cognitive deficits. Yet it is difficult to diagnose because of confounding clinical manifestations similar in other dementias. Clinicians thus resort to the longitudinal neurologic observation of disease progression, associated with biological markers such as Aβ 1-42, t-tau and p-tau CSF level and the measure of associated neuroanatomical insults using neuroimaging. Mild cognitive impairment (MCI) precedes AD, but is also present during normal or pathological ageing associated with other dementias. Over the course of 5 years, 50 to 70% of MCI patients will develop AD. ICDD is interested in the identification of prodromal markers of AD associated with disease progression. ICDD is a partner of the IMI/PharmaCog, consortium dedicated to the identification of new tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. For this purpose, specific and robust biological markers are needed to follow disease progression and its potential reversal by disease-modifying drugs. Our efforts are focused on the validation of a novel set of inflammatory blood markers within a cohort of 150 patients followed longitudinally for 3 years. An overview of the validation stage of existing blood biomarkers is presented, with a particular focus on inflammation markers. We will also present the two discovery platforms used to generate the marker sets being validated in the PharmaCog consortium using proprietary cellulomic and proteomic technologies.
